Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    March 2021
  1. WENZEL L, Osann K, McKinney C, Cella D, et al
    Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
    J Natl Cancer Inst. 2021 Mar 17. pii: 6174697. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  2. PERES LC, Bethea TN, Camacho TF, Bandera EV, et al
    Racial differences in population attributable risk for epithelial ovarian cancer in the OCWAA Consortium.
    J Natl Cancer Inst. 2020 Nov 30. pii: 6012358. doi: 10.1093.
    PubMed     Abstract available


  3. SPAAN M, van den Belt-Dusebout AW, Lambalk CB, van Boven HH, et al
    Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology.
    J Natl Cancer Inst. 2020 Nov 17. pii: 5981708. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  4. LEE AW, Rosenzweig S, Wiensch A, Ramus SJ, et al
    Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies.
    J Natl Cancer Inst. 2020 Aug 7. pii: 5885090. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  5. KALACHAND RD, Stordal B, Madden S, Chandler B, et al
    BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.
    J Natl Cancer Inst. 2020 May 15. pii: 5837681. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  6. VOS JR, Ligtenberg MJL, Hoogerbrugge N
    Response to Tomao, Panici, and Tomao.
    J Natl Cancer Inst. 2020;112:425.
    PubMed    


    February 2020
  7. YANG X, Song H, Leslie G, Engel C, et al
    Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
    J Natl Cancer Inst. 2020 Feb 28. pii: 5764125. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  8. VERDOODT F, Dehlendorff C, Jaattela M, Strauss R, et al
    Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay.
    J Natl Cancer Inst. 2019 Nov 5. pii: 5613208. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  9. ZELEZNIK OA, Clish CB, Kraft P, Avila-Pancheco J, et al
    Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: a 23-year Prospective Study.
    J Natl Cancer Inst. 2019 Oct 8. pii: 5583767. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  10. TOMAO F, Panici PB, Tomao S
    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    J Natl Cancer Inst. 2019 Jul 9. pii: 5530203. doi: 10.1093.
    PubMed    


    June 2019
  11. VAN DIEST PJ, Zweemer RP, Piek JMJ
    Re: the Association between hysterectomy and ovarian cancer risk: A population-based record-linkage study.
    J Natl Cancer Inst. 2019 Jun 13. pii: 5514539. doi: 10.1093.
    PubMed    


    May 2019
  12. VOS JR, Fakkert IE, de Hullu JA, van Altena AM, et al
    Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    J Natl Cancer Inst. 2019 May 11. pii: 5488012. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  13. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  14. DIXON-SUEN SC, Webb PM, Wilson LF, Tuesley K, et al
    The Association between hysterectomy and ovarian cancer risk: A population-based record-linkage study.
    J Natl Cancer Inst. 2019 Feb 11. pii: 5308404. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  15. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    PubMed     Abstract available


    June 2018

  16. Corrigendum to "Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer".
    J Natl Cancer Inst. 2018 Jun 28. pii: 5046631. doi: 10.1093.
    PubMed    


    May 2018
  17. YEUNG TL, Sheng J, Leung CS, Li F, et al
    Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
    J Natl Cancer Inst. 2018 May 31. pii: 5026201. doi: 10.1093.
    PubMed     Abstract available


  18. TRABERT B, Poole EM, White E, Visvanathan K, et al
    Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
    J Natl Cancer Inst. 2018 May 31. pii: 5026198. doi: 10.1093.
    PubMed     Abstract available


  19. TRABERT B, Waterboer T, Idahl A, Brenner N, et al
    Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.
    J Natl Cancer Inst. 2018 May 21. pii: 5001107. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  20. CRAMER DW, Elias KM
    Perspectives on Ovarian Cancer From SEER: Today and Tomorrow.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990609. doi: 10.1093.
    PubMed    


  21. PERES LC, Cushing-Haugen KL, Kobel M, Harris HR, et al
    Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990606. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  22. HILLMAN RT, Chisholm GB, Lu KH, Futreal PA, et al
    Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    December 2017
  23. VISVANATHAN K, Wang TL, Shih IM
    Precancerous Lesions of Ovarian Cancer-A US Perspective.
    J Natl Cancer Inst. 2017 Dec 21. pii: 4769851. doi: 10.1093.
    PubMed    


    November 2017
  24. FERRARA N
    Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
    J Natl Cancer Inst. 2017;109.
    PubMed    


  25. BAIS C, Mueller B, Brady MF, Mannel RS, et al
    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    October 2017
  26. DOHERTY JA, Jensen A, Kelemen LE, Pearce CL, et al
    Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    August 2017
  27. SCHMIDT MK, van den Broek AJ, Tollenaar RA, Smit VT, et al
    Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    July 2017
  28. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


  29. PREVIS RA, Armaiz-Pena GN, Ivan C, Dalton HJ, et al
    Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    March 2017
  30. BRASKY TM, Felix AS, Cohn DE, McMeekin DS, et al
    Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
    J Natl Cancer Inst. 2017;109:1-10.
    PubMed     Abstract available


    October 2016
  31. FILLON M
    New Guidelines for Treating Ovarian Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: